Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
UNICHEM LABORATORIES LIMITED has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 3 distinct examiners and 3 distinct art units, indicating separate examination paths across the active portfolio.
REYNOLDS, FRED H is the busiest examiner, with 1 pending matter. Counsel should coordinate the docket centrally while developing examiner- and art-unit-specific responses.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 33.2% | +39.7% |
| DICKENS, AMELIA NICOLE | 1 | 47.7% | +22.5% |
| SCHWECHTER, BRANDON ROSS | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260404 | LECTIN PROTEIN FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | SCHWECHTER, BRANDON ROSS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691412 | RECOMBINANT GLYCAN BINDING PROTEINS AND ITS USE | DICKENS, AMELIA NICOLE | 25d overdue |
| 18718862 | RECOMBINANT PROTEIN FOR SARS-COV2 DISEASE | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1645 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18718862 | RECOMBINANT PROTEIN FOR SARS-COV2 DISEASE | REYNOLDS, FRED H | 1658 | §102§112DP | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18691412 | RECOMBINANT GLYCAN BINDING PROTEINS AND ITS USE | DICKENS, AMELIA NICOLE | 1645 | §102Other | Final Rejection | 25d overdue | Pending | Mar 12, 2024 |
| 18260404 | LECTIN PROTEIN FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | SCHWECHTER, BRANDON ROSS | 1674 | §112 | Final Rejection | — | Pending | Jul 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNICHEM LABORATORIES LIMITED has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.
Fred H Reynolds has the most, with 1 of UNICHEM LABORATORIES LIMITED's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.